Engitix has inked an R&D deal focused on fibrosis and liver tumors with new investor Dompé Farmaceutici S.p.A. that it hopes will facilitate the UK biotech’s transition from a technology platform to a clinical product company, as it raised $54m in a series A financing.
Under the collaboration, Engitix will retain full control over its assets and programs while Dompé could receive clinical and commercial milestone payments and royalties on products developed by the duo. “The typical deal for an early-stage biotech involves out-licensing programs to big pharma but we thought it was very important to develop our internal pipeline to create long-term value,” Engitix CEO Giuseppe Mazza told Scrip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?